Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GSE SYSTEMS INCGVP · Entity 87144 | Director | June 11, 2019 | June 12, 2019 |
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Chief Financial Officer | April 05, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GSE SYSTEMS INC
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,118 |
Reported balance
After 2019-06-11 transaction · row 1
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 25,316 · Balance 48,118 F1: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders. F2: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders.
F2: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.
Processa Pharmaceuticals, Inc.
Report date April 05, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,482 |
Ending reported balance
After 2024-07-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-04-05 · Exercise / conversion · Acquired 1,675 · Balance 6,638 F1: Distribution of vested restricted shares. Row 2 · 2024-04-05 · Tax withholding · Disposed 518 · Balance 6,120 Row 3 · 2024-07-10 · Exercise / conversion · Acquired 644 · Balance 6,764 F1: Distribution of vested restricted shares. Row 4 · 2024-07-10 · Tax withholding · Disposed 282 · Balance 6,482 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 26,470 |
Reported balance
After 2024-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-28 · Grant · Acquired 3,077 · Balance 26,470 F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 28,777 |
Reported balance
After 2024-06-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-28 · Grant · Acquired 2,307 · Balance 28,777 F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 29,162 |
Reported balance
After 2024-06-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-28 · Grant · Acquired 385 · Balance 29,162 F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 29,547 |
Reported balance
After 2024-06-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-06-28 · Grant · Acquired 385 · Balance 29,547 F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of vested restricted shares.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 282 | $1.71 | $482.22 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 4 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,482 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 3 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 8 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,547 Underlying: Common Stock · 385 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 7 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,162 Underlying: Common Stock · 385 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,307 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 6 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,777 Underlying: Common Stock · 2,307 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 3,077 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · derivative · entry 5 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,470 Underlying: Common Stock · 3,077 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,120 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 17:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 16:57 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000923 · form4.xml · derivative · entry 3 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,037 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 16:57 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-000923 · form4.xml · nonDerivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,120 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 16:57 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000923 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 17:58 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 15,000 | $0.33 | $4,950.00 |
DisclosureSEC source: 0000897069-23-001464 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,250 Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 16:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 22,500 | $0.24 | $5,400.00 |
DisclosureSEC source: 0000897069-23-001436 · form4.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,250 Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 17:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 12,500 | $0.80 | $10,000.00 |
DisclosureSEC source: 0001567619-23-002403 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,750 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 17:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 96,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000324 · doc1.xml · derivative · entry 3 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,431 Underlying: Common Stock · 96,150 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 17:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 69,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000324 · doc1.xml · derivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,281 Underlying: Common Stock · 69,667 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 17:42 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,951 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000324 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,614 Underlying: Common Stock · 12,951 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date grant. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date grant. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 16:40 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,950 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018275 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,663 Underlying: Common Stock · 12,950 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: Previous filing inadvertently underreported derivative securities beneficially owned by the reporting person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 2,462 | $3.17 | $7,804.54 |
DisclosureSEC source: 0001567619-22-015307 · doc1.xml · nonDerivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,250 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015307 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 17:35 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 23,947 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013682 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,713 Underlying: Common Stock · 23,947 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| June 30, 2022 Filed Oct 3, 2022 16:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 23,947 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018057 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,713 Underlying: Common Stock · 23,947 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| April 01, 2022 Filed Apr 11, 2022 17:54 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 247,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008365 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,766 Underlying: Common Stock · 247,841 shares Expires not disclosed F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007982 · doc1.xml · derivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,781 Underlying: Common Stock · 10,715 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:27 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000294 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 17:21 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000766 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| November 01, 2021 Filed Apr 4, 2022 17:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 4,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007982 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,066 Underlying: Common Stock · 4,286 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 16:38 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-017827 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,024 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| September 30, 2021 Filed Jan 6, 2022 16:07 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000724 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,058 Underlying: Common Stock · 6,024 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 16:38 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014749 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,111 F1 · price: Vesting of time-based restricted shares. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 16:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,907 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013183 · doc1.xml · derivative · entry 3 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 16:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 12,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013183 · doc1.xml · derivative · entry 2 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,858 Underlying: Common Stock · 12,858 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals. F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 16:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013183 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,572 Underlying: Common Stock · 8,572 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022. F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,000 | $6.81 | $6,810.00 |
DisclosureSEC source: 0001567619-21-012484 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,510 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.72 to $6.89, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 17:06 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,127 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011980 · doc1.xml · derivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 8,127 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 17:33 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 6,000 | $4.00 | $24,000.00 |
DisclosureSEC source: 0001567619-20-017592 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,248 F1 · price: This amended Form 4 is being filed to correct the purchase price for the reported transaction. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:43 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 6,000 | $2.10 | $12,600.00 |
DisclosureSEC source: 0001567619-20-017574 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,248 Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 16:23 UTC | GSE SYSTEMS INC GVP · Entity 87144 | GrantCommon Stock | 25,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013279 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,118 F1 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders. F2 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 17:13 UTC | GSE SYSTEMS INC GVP · Entity 87144 | GrantCommon Stock | 7,911 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-028441 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,802 F1 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 12, 2019 or the date of the Issuer's 2019 Annual Meeting of Stockholders. F2 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:21 UTC | GSE SYSTEMS INC GVP · Entity 87144 | GrantCommon Stock | 7,352 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024983 · doc1.xml · nonDerivative · entry 2 Stanker James H · CIK 0001681718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,891 F2 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 7, 2018 or the date of the Issuer's 2018 Annual Meeting of Stockholders. F3 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 16:21 UTC | GSE SYSTEMS INC GVP · Entity 87144 | GrantCommon Stock | 1,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024983 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,539 F1 · shares: Shares of Common Stock granted to Mr. Stanker on June 12, 2017, in partial compensation for the Mr. Stanker's service as a member of the Issuer's Board of Directors between March 1, 2017 and June 12, 2017. F1 · price: Shares of Common Stock granted to Mr. Stanker on June 12, 2017, in partial compensation for the Mr. Stanker's service as a member of the Issuer's Board of Directors between March 1, 2017 and June 12, 2017. Read SEC document |
| December 08, 2016 Filed Dec 12, 2016 17:07 UTC | GSE SYSTEMS INC GVP · Entity 87144 | GrantCommon Stock | 5,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-089399 · doc1.xml · nonDerivative · entry 1 Stanker James H · CIK 0001681718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,616 F1 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 7, 2017 or the date of the Issuer's 2017 Annual Meeting of Stockholders. F2 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.